Payment overview · 2025
General Payments
$329.52
18 reported records · 6 companies
Healthcare provider profile · identity verified
Eric W Graves, MD
Allopathic & Osteopathic Physicians|Family Medicine · MONTGOMERY, AL · NPI 1871574517
Verified facts
What the public records show
CMS Open Payments records show Eric W Graves, MD received $329.52 in general payments during 2025 across 18 reported records.
ABBVIE INC. accounted for 35.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $117.56 | 35.7% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $78.34 | 23.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $58.14 | 17.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.65 | 12.3% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $17.98 | 5.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.85 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $329.52 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $117.56 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $58.14 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $58.14 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.99 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $42.27 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $36.07 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $36.07 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 339 | 54 |
| Atorvastatin Calcium | Atorvastatin Calcium | 328 | 101 |
| Simvastatin | Simvastatin | 272 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 227 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 222 | 75 |
| Zolpidem Tartrate | Zolpidem Tartrate | 211 | 36 |
| Omeprazole | Omeprazole | 203 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 184 | 58 |
| Losartan Potassium | Losartan Potassium | 167 | 53 |
| Metformin Hcl | Metformin Hcl | 127 | 38 |
| Montelukast Sodium | Montelukast Sodium | 118 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 114 | 31 |
| Carvedilol | Carvedilol | 109 | 27 |
| Potassium Chloride | Potassium Chloride | 106 | 34 |
| Meloxicam | Meloxicam | 101 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 97 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 77 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 16 |
| Lisinopril | Lisinopril | 74 | 23 |
| Ramipril | Ramipril | 69 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 68 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 60 | 18 |
| Clonazepam | Clonazepam | 60 | suppressed |
| Furosemide | Furosemide | 60 | 19 |
| Pregabalin | Pregabalin | 58 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 14 |
| Atenolol | Atenolol | 54 | 16 |
| Cefprozil | Cefprozil | 54 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 22 |
| Trazodone Hcl | Trazodone Hcl | 53 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 14 |
| Ozempic | Semaglutide | 51 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 47 | 15 |
| Sertraline Hcl | Sertraline Hcl | 47 | 15 |
| Levofloxacin | Levofloxacin | 45 | 29 |
| Tramadol Hcl | Tramadol Hcl | 45 | 15 |
| Allopurinol | Allopurinol | 43 | 11 |
| Lorazepam | Lorazepam | 43 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 43 | suppressed |
| Valsartan | Valsartan | 43 | 14 |
| Famotidine | Famotidine | 42 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Temazepam | Temazepam | 39 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | 28 |
| Alendronate Sodium | Alendronate Sodium | 38 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 13 |
| Azithromycin | Azithromycin | 37 | 31 |
| Ezetimibe | Ezetimibe | 36 | 11 |
| Gabapentin | Gabapentin | 36 | 15 |
| Methylprednisolone | Methylprednisolone | 36 | 31 |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Telmisartan | Telmisartan | 33 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 29 | 12 |
| Fluconazole | Fluconazole | 29 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | 19 |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Klor-Con 10 | Potassium Chloride | 20 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Eliquis | Apixaban | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 11 |
| Cephalexin | Cephalexin | 15 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $329.52 · 18 records | ABBVIE INC. | AREXVY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, KRYSTEXXA, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error